quality systems process, if you think of it. We get consumer complaints. We get complaints that this product didn't work as it was expected to, and how do we resolve that? How do we distinguish between whether this is a perception issue or whether it's truly a quality issue and truly that we need to change? We took a step back, looked at the whole process, and we will sort of bring some of that discussion to the Biopharmaceutics Subcommittee, also.
But some of the research activities at the OPS level are focused on rapid response situations. This is one of the examples of the rapid response things that we do, but there are others. Some of them are related to counter-terrorism issues and Nakissa will give you some examples so that you appreciate the quality systems approach that is evolving, which is also sort of building on what we have today.
So that's what we have in store for you today, and I hope it will be a very productive discussion.
DR. KIBBE: Thank you, Ajaz.
Is there anyone who has any questions for Ajaz?